knowledge -WSS

knowledge

author：entertainment 2025-10-06 14:55:57 - browse：59

A view of different flags of the European Union Members. -- first opinion coverage from STAT — Ronald Wittek, Pool Photo via AP

Today, the criteria used to assess the clinical value of new pharmaceuticals and medical devices varies widely across Europe, making it more challenging for biopharma companies to efficiently launch products in multiple countries and contributing to the disparities in access across the continent.

But change is on the horizon: In less than 15 months, the European Union will establish and begin to implement a standardized, pan-EU framework, which all 27 of member states will be required to use to assess the clinical evidence of newly submitted products or devices. A key pillar of the EU’s Regulation on Health Technology Assessment (HTA), the Joint Clinical Assessment (JCA) aims to establish a single, transparent process to reduce redundant practices and bring life science innovation faster to patients in Europe — no matter where they live.

In a longstanding problem in Europe, access to — and the availability of — medication varies across the member states. For example, in Germany, 87% of products approved by the European Medicines Agency (EMA) have full availability (the product gained access on the public reimbursement list without any restrictions to the patient population). In Poland, that figure drops to 8%, according to a report published by the European Federation of Pharmaceutical Industries. Meanwhile, there is a tremendous difference in the gap between an oncology therapy receiving marketing authorization and a formal positive reimbursement decision, ranging from an average of 86 days in Denmark to 981 days in Latvia.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Readout Newsletter: Sanofi, Novavax, Maze x Shionogi news

WSS

After gene therapy, two congenitally deaf children hear for the first time

Sanofi strikes deal with Novavax, boosting the vaccine maker

After gene therapy, two congenitally deaf children hear for the first time

Gritstone Bio's cancer vaccine test, and more on Novartis' deal

H5N1 communication has been strictly for the birds

Medicare Advantage plans can’t deny care with AI, CMS warns

explore

knowledge

focus

State Dept. review finds Biden bears some blame for Afghanistan failures

Unique patient identifier: Experts argue the benefits, pitfalls

How to save PrEP access — and even expand it

Steward Health Care files for bankruptcy

Wildfire smoke exposes gaps in outdoor worker protections

Texas Medical Board asked to define abortion emergency exception

Cancer drug shortages should be causing more outrage

Readout LOUD podcast: What to know about H5N1 bird flu

United colonoscopy coverage change 'may cost lives,' doctors say

Problems with a popular proposal to regulate AI in health care

hotspot

Readout Newsletter: Sanofi, Novavax, Maze x Shionogi news

Texas Medical Board asked to define abortion emergency exception

CDC wastewater surveillance dashboard to track bird flu hotspots

Bernie brings in new pharma CEOs to talk drug prices

Readout Newsletter: Sanofi, Novavax, Maze x Shionogi news

Unique patient identifier: Experts argue the benefits, pitfalls

leisure time

explore

focus

Wikipedia